2seventy bio, Inc. (TSVT)
(Delayed Data from NSDQ)
$5.05 USD
+0.18 (3.70%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $5.06 +0.01 (0.20%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TSVT 5.05 +0.18(3.70%)
Will TSVT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TSVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TSVT
Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated
2seventy bio, Inc. (TSVT) Reports Q2 Loss, Lags Revenue Estimates
TSVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is the Options Market Predicting a Spike in 2seventy bio (TSVT) Stock?
Will 2seventy bio, Inc. (TSVT) Report Negative Q2 Earnings? What You Should Know
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates
Other News for TSVT
TSVT Makes Notable Cross Below Critical Moving Average
2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference
2seventy bio, Inc. (TSVT) Q2 2024 Earnings Call Transcript
Leerink Partners Keeps Their Buy Rating on 2seventy bio (TSVT)
Analysts Offer Insights on Healthcare Companies: 2seventy bio (TSVT), Illumina (ILMN) and Larimar Therapeutics (LRMR)